Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Argent Biopharma ( (AU:RGT) ).
Argent BioPharma Ltd reported a significant decrease in revenue by 80% to A$0.18 million for the financial year ending June 30, 2025, compared to the previous year. This decline is attributed to the company’s strategic decision to shift away from non-core activities and concentrate on its development pipeline. Despite a 2% increase in net loss to A$17.84 million, these results align with the company’s strategic direction of investing in clinical and regulatory programs. The company remains focused on advancing its drug candidates and believes the recent restructuring will provide a strong foundation for future growth.
More about Argent Biopharma
Argent BioPharma Ltd operates in the biopharmaceutical industry, focusing on the development of innovative, multidisciplinary drug candidates aimed at addressing unmet medical needs. The company is committed to advancing its research and development pipeline, having undergone corporate restructuring to support long-term growth.
Average Trading Volume: 85,981
Technical Sentiment Signal: Sell
Current Market Cap: A$8.34M
See more data about RGT stock on TipRanks’ Stock Analysis page.